Guselkumab Boosts Response in Resistant Psoriatic Arthritis

NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Source Type: research